Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

• Published in: Future Oncology Vol. 19; no. 34; pp. 2277 - 2289
• Main Authors: Do-Youn, Oh, Aiwu Ruth, He, Shukui, Qin, Li-Tzong, Chen, Takuji, Okusaka, Arndt, Vogel, Jin Won, Kim, Thatthan, Suksombooncharoen, Myung Ah, Lee, Masayuki, Kitano, Howard, Burris, Mohamed, Bouattour, Suebpong, Tanasanvimon, Mairead G, McNamara, Renata, Zaucha, Antonio, Avallone, Benjamin, Tan, Juan, Cundom, Choong-Kun, Lee, Hidenori, Takahashi, Masafumi, Ikeda, Jen-Shi, Chen, Julie, Wang, Mallory, Makowsky, Nana, Rokutanda, Magdalena, Żotkiewicz, John F, Kurland, Gordon, Cohen, Juan W, Valle
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.11.2023; Informa UK Limited
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - adverse effects; bile duct cancer; Bile Duct Neoplasms; Bile Duct Neoplasms - drug therapy; biliary tract cancer; Biliary Tract Neoplasms; Biliary Tract Neoplasms - drug therapy; chemotherapy; cholangiocarcinoma; Cisplatin; Deoxycytidine; durvalumab; Gemcitabine; Humans; ICTS (Institute of Clinical and Translational Sciences); immunotherapy; lay summary; Medicine and Health Sciences; plain language summary; biliary tract cancer; durvalumab; immunotherapy; bile duct cancer; gemcitabine; cisplatin; chemotherapy; cholangiocarcinoma; lay summary; plain language summary

This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it...